TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

04 4 2022 16:05:00 提供 Nasdaq GlobeNewswire

Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201

21 3 2022 16:05:00 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

03 3 2022 16:05:01 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference

28 2 2022 16:05:01 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer

06 1 2022 07:05:00 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference

03 1 2022 16:05:00 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

15 11 2021 16:05:00 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021

12 11 2021 07:05:00 提供 Nasdaq GlobeNewswire

Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501

09 11 2021 16:05:01 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experience 2021

18 10 2021 16:05:00 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

05 10 2021 16:05:00 提供 Nasdaq GlobeNewswire

Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors

28 9 2021 16:05:00 提供 Nasdaq GlobeNewswire

Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

08 9 2021 07:05:00 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

02 9 2021 16:05:00 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

16 8 2021 16:05:00 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

03 8 2021 16:05:00 提供 Nasdaq GlobeNewswire

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

24 6 2021 16:05:00 提供 Nasdaq GlobeNewswire

Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH

14 6 2021 07:05:00 提供 Nasdaq GlobeNewswire

Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH

13 6 2021 17:00:00 提供 Nasdaq GlobeNewswire

Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series

19 5 2021 17:00:00 提供 Nasdaq GlobeNewswire